Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Classical homeopathy in the treatment of cancer patients - a prospective observational study of two independent cohorts

Authors: Matthias Rostock, Johannes Naumann, Corina Guethlin, Lars Guenther, Hans H Bartsch, Harald Walach

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Many cancer patients seek homeopathy as a complementary therapy. It has rarely been studied systematically, whether homeopathic care is of benefit for cancer patients.

Methods

We conducted a prospective observational study with cancer patients in two differently treated cohorts: one cohort with patients under complementary homeopathic treatment (HG; n = 259), and one cohort with conventionally treated cancer patients (CG; n = 380). For a direct comparison, matched pairs with patients of the same tumour entity and comparable prognosis were to be formed.
Main outcome parameter: change of quality of life (FACT-G, FACIT-Sp) after 3 months.
Secondary outcome parameters: change of quality of life (FACT-G, FACIT-Sp) after a year, as well as impairment by fatigue (MFI) and by anxiety and depression (HADS).

Results

HG: FACT-G, or FACIT-Sp, respectively improved statistically significantly in the first three months, from 75.6 (SD 14.6) to 81.1 (SD 16.9), or from 32.1 (SD 8.2) to 34.9 (SD 8.32), respectively. After 12 months, a further increase to 84.1 (SD 15.5) or 35.2 (SD 8.6) was found. Fatigue (MFI) decreased; anxiety and depression (HADS) did not change.
CG: FACT-G remained constant in the first three months: 75.3 (SD 17.3) at t0, and 76.6 (SD 16.6) at t1. After 12 months, there was a slight increase to 78.9 (SD 18.1). FACIT-Sp scores improved significantly from t0 (31.0 - SD 8.9) to t1 (32.1 - SD 8.9) and declined again after a year (31.6 - SD 9.4). For fatigue, anxiety, and depression, no relevant changes were found.
120 patients of HG and 206 patients of CG met our criteria for matched-pairs selection. Due to large differences between the two patient populations, however, only 11 matched pairs could be formed. This is not sufficient for a comparative study.

Conclusion

In our prospective study, we observed an improvement of quality of life as well as a tendency of fatigue symptoms to decrease in cancer patients under complementary homeopathic treatment. It would take considerably larger samples to find matched pairs suitable for comparison in order to establish a definite causal relation between these effects and homeopathic treatment.
Appendix
Available only for authorised users
Literature
1.
Molassiotis A, Fernadez-Ortega P, Pud D, et al: Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005, 16: 655-663. 10.1093/annonc/mdi110.CrossRefPubMed
2.
Frenkel M: Homeopathy in cancer care. Altern Ther Health Med. 16: 12-16.
3.
Walach H, Jonas WB, Ives J, et al: Research on homeopathy: state of the art. J Altern Complement Med. 2005, 11: 813-829. 10.1089/acm.2005.11.813.CrossRefPubMed
4.
Jonas WB, Kaptchuk TJ, Linde K: A critical overview of homeopathy. Ann Intern Med. 2003, 138: 393-399.CrossRefPubMed
5.
Linde K, Clausius N, Ramirez G, et al: Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet. 1997, 350: 834-843. 10.1016/S0140-6736(97)02293-9.CrossRefPubMed
6.
Shang A, Huwiler-Müntener K, Nartey L, et al: Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy. Lancet. 2005, 366: 726-732. 10.1016/S0140-6736(05)67177-2.CrossRefPubMed
7.
Ludtke R, Rutten AL: The conclusions on the effectiveness of homeopathy highly depend on the set of analyzed trials. J Clin Epidemiol. 2008, 61: 1197-1204. 10.1016/j.jclinepi.2008.06.015.CrossRefPubMed
8.
Kassab S, Cummings M, Berkovitz S, et al: Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev. 2009, CD004845
9.
Milazzo S, Russell N, Ernst E: Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer. 2006, 42: 282-289. 10.1016/j.ejca.2005.09.025.CrossRefPubMed
10.
Jacobs J, Herman P, Heron K, et al: Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. J Altern Complement Med. 2005, 11: 21-27. 10.1089/acm.2005.11.21.CrossRefPubMed
11.
Thompson EA, Montgomery A, Douglas D, Reilly D: A pilot randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. J Altern Complement Med. 2005, 11: 13-20. 10.1089/acm.2005.11.13.CrossRefPubMed
12.
Spinedi D: Die Krebsbehandlung in der Homöopathie. 1999, Kempten: Cheiron Verlag, In Edition
13.
Takacs M: Erfahrungen bei der Krebsbehandlung in der Clinica Santa Croce (Orselina, Schweiz). Allgemeine Homöopathische Zeitung. 2004, 249: 232-239.CrossRef
14.
Walach H, Haeusler W, Lowes T, et al: Classical homeopathic treatment of chronic headaches. Cephalalgia. 1997, 17: 119-126. 10.1046/j.1468-2982.1997.1702119.x. discussion 101CrossRefPubMed
15.
Mitzdorf U, Beck K, Horton-Hausknecht J, et al: Why do patients seek treatment in hospitals of complementary medicine?. J Altern Complement Med. 1999, 5: 463-473. 10.1089/acm.1999.5.463.CrossRefPubMed
16.
Rostock M, Huber R: Randomized and double-blind studies--demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementarmed Klass Naturheilkd. 2004, 11 (Suppl 1): 18-22. 10.1159/000080571.CrossRefPubMed
17.
Katz T, Fisher P, Katz A, et al: The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. Homeopathy. 2005, 94: 145-152. 10.1016/j.homp.2005.04.002.CrossRefPubMed
18.
Lüdtke R, Schmück M, Gerhard I: Methodische Überlegungen zum Wirksamkeitsnachweis der homöopathischen Einzelmittelbehandlung von Zyklusstörungen. Forschende Komplementärmedizin. 1997, 4: 28-32.CrossRef
19.
von Rohr E, Pampallona S, van Wegberg B, et al: Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweiz Med Wochenschr. 2000, 130: 1173-1184.PubMed
20.
Gerhard I, Abel U, Loewe-Mesch A, et al: Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd. 2004, 11: 150-157. 10.1159/000079444.CrossRefPubMed
21.
Walach H, Falkenberg T, Fonnebo V, et al: Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006, 6: 29-10.1186/1471-2288-6-29.CrossRefPubMedPubMedCentral
22.
Guethlin C, Walach H, Naumann J, et al: Characteristics of cancer patients using homeopathy compared with those in conventional care: a cross-sectional study. Ann Oncol. 2010, 21: 1094-1099. 10.1093/annonc/mdp421.CrossRefPubMed
23.
Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993, 11: 570-579.PubMed
24.
Peterman AH, Fitchett G, Brady MJ, et al: Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med. 2002, 24: 49-58. 10.1207/S15324796ABM2401_06.CrossRefPubMed
25.
Smets EM, Garssen B, Bonke B, De Haes JC: The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995, 39: 315-325. 10.1016/0022-3999(94)00125-O.CrossRefPubMed
26.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67: 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed
27.
Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002, 11: 207-221. 10.1023/A:1015276414526.CrossRefPubMed
28.
Purcell A, Fleming J, Bennett S, et al: Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population. Support Care Cancer. 18: 307-315. 10.1007/s00520-009-0653-z.
29.
Cella D, Eton DT, Lai JS, et al: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002, 24: 547-561. 10.1016/S0885-3924(02)00529-8.CrossRefPubMed
30.
King MT, Fayers PM: Making quality-of-life results more meaningful for clinicians. Lancet. 2008, 371: 709-710. 10.1016/S0140-6736(08)60324-4.CrossRefPubMed
31.
Webster K, Cella D, Yost K: The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003, 1: 79-10.1186/1477-7525-1-79.CrossRefPubMedPubMedCentral
32.
Yost KJ, Eton DT: Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005, 28: 172-191. 10.1177/0163278705275340.CrossRefPubMed
33.
Aickin M: Randomization, balance, and the validity and efficiency of design-adaptive allocation methods. Journal of Statistical Planning and Inference. 2001, 94: 97-119. 10.1016/S0378-3758(00)00228-7.CrossRef
34.
Moerman DE, Jonas WB: Deconstructing the placebo effect and finding the meaning response. Ann Intern Med. 2002, 136: 471-476.CrossRefPubMed
Metadata
Title
Classical homeopathy in the treatment of cancer patients - a prospective observational study of two independent cohorts
Authors
Matthias Rostock
Johannes Naumann
Corina Guethlin
Lars Guenther
Hans H Bartsch
Harald Walach
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-19

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

The association of APE1 −656T > G and 1349 T > G polymorphisms and cancer risk: a meta-analysis based on 37 case-control studies

Research article

The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells

Case report

Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review

Research article

Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area

Research article

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Research article

Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits